Published Online
on January 3, 2006

A more recent version of this article appeared on January 17, 2006

This Article Full Text (PDF) All Versions of this Article: 113/2/273    most recent CIRCULATIONAHA.105.575977v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mehilli, J. Search for Related Content PubMed PubMed Citation Articles by Mehilli, J. Related Collections Catheter-based coronary interventions: stents Restenosis Related Article

Submitted on July 14, 2005
Revised on October 4, 2005
Accepted on November 7, 2005

Randomized Trial of a Nonpolymer-Based Rapamycin-Eluting Stent Versus a Polymer-Based Paclitaxel-Eluting Stent for the Reduction of Late Lumen Loss

Julinda Mehilli MD, Adnan Kastrati MD, Rainer Wessely MD, Alban Dibra MD, Jörg Hausleiter MD, Birgit Jaschke PhD, Josef Dirschinger MD, Albert Schömig MD^*, for the Intracoronary Stenting and Angiographic Restenosis-Test Equivalence Between 2 Drug-Eluting Stents (ISAR-TEST) Trial Investigators

From the Deutsches Herzzentrum (J.M., A.K., R.W., A.D., J.H., B.J., A.S.) and Medizinische Klinik I rechts der Isar (J.D., A.S.), Technische Universität, Munich, Germany.

^* To whom correspondence should be addressed. E-mail: aschoemig{at}dhm.mhn.de.

Background--Although drug-eluting stents (DESs) constitute a major achievement in preventing restenosis, concerns remain regarding the increased inflammatory and thrombogenic responses associated with the polymers used. Recently, we showed that a nonpolymer on-site coating with rapamycin not only is feasible and safe but also leads to a dose-dependent reduction in restenosis.

Methods and Results--To assess whether polymer-free stents coated on-site with 2% rapamycin solution are inferior to polymer-based paclitaxel-eluting stents for the prevention of restenosis, we randomly assigned a total of 450 patients with de novo lesions in native coronary vessels, excluding the left main trunk, to either the polymer-free, rapamycin-coated Yukon DES (rapamycin stent) or the polymer-based, paclitaxel-eluting Taxus stent (paclitaxel stent). The primary end point was in-stent late lumen loss. Secondary end points were angiographic restenosis and target lesion revascularization. The study was designed to test the noninferiority of the rapamycin stent compared with the paclitaxel stent with respect to late lumen loss according to a noninferiority margin of 0.13 mm. Follow-up angiography was completed in 81% of the patients. The mean difference in in-stent late lumen loss between the rapamycin-stent group and the paclitaxel-stent group was 0.002 mm, and the upper limit of the 1-sided 95% confidence interval was 0.10 mm (P=0.02 from test for noninferiority). No significant differences were observed regarding angiographic restenosis rates (14.2% with the rapamycin stent and 15.5% with the paclitaxel stent) and target lesion revascularization rates due to restenosis (9.3% in both groups).

Conclusions--The polymer-free, rapamycin-coated stent has an antirestenotic effect that is not inferior to that observed with the polymer-based paclitaxel-eluting stent.

Key words: coronary disease • restenosis • stents • drugs

Related Article:

Issue Highlights
Circulation 2006 113: 177. [Full Text]

This article has been cited by other articles:

				E. Mahmud, G. Bromberg-Marin, V. Palakodeti, L. Ang, D. Creanga, and A. N. DeMaria Clinical efficacy of drug-eluting stents in diabetic patients: a meta-analysis. J. Am. Coll. Cardiol., June 24, 2008; 51(25): 2385 - 2395. [Abstract] [Full Text] [PDF]

				J. Mehilli, R. A. Byrne, A. Wieczorek, R. Iijima, S. Schulz, O. Bruskina, J. Pache, R. Wessely, A. Schomig, A. Kastrati, et al. Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis Eur. Heart J., June 11, 2008; (2008) ehn253v1. [Abstract] [Full Text] [PDF]

				S. R. Dixon, C. L. Grines, and W. W. O'Neill The Year in Interventional Cardiology J. Am. Coll. Cardiol., July 17, 2007; 50(3): 270 - 285. [Full Text] [PDF]

				J. Daemen and P. W. Serruys Drug-Eluting Stent Update 2007: Part I: A Survey of Current and Future Generation Drug-Eluting Stents: Meaningful Advances or More of the Same? Circulation, July 17, 2007; 116(3): 316 - 328. [Full Text] [PDF]

				R. Moreno, C. Fernandez, A. Sanchez-Recalde, G. Galeote, L. Calvo, F. Alfonso, R. Hernandez, R. Sanchez-Aquino, D. J. Angiolillo, S. Villarreal, et al. Clinical impact of in-stent late loss after drug-eluting coronary stent implantation Eur. Heart J., July 1, 2007; 28(13): 1583 - 1591. [Abstract] [Full Text] [PDF]

				T. Adriaenssens, J. Mehilli, R. Wessely, G. Ndrepepa, M. Seyfarth, A. Wieczorek, B. Blaich, R. Iijima, J. Pache, A. Kastrati, et al. Does Addition of Estradiol Improve the Efficacy of a Rapamycin-Eluting Stent?: Results of the ISAR-PEACE Randomized Trial J. Am. Coll. Cardiol., March 27, 2007; 49(12): 1265 - 1271. [Abstract] [Full Text] [PDF]

				D. O. Williams, J. D. Abbott, K. E. Kip, and for the DEScover Investigators Outcomes of 6906 Patients Undergoing Percutaneous Coronary Intervention in the Era of Drug-Eluting Stents: Report of the DEScover Registry Circulation, November 14, 2006; 114(20): 2154 - 2162. [Abstract] [Full Text] [PDF]

				S. Elezi, A. Dibra, J. Mehilli, J. Pache, R. Wessely, A. Schomig, and A. Kastrati Vessel Size and Outcome After Coronary Drug-Eluting Stent Placement: Results From a Large Cohort of Patients Treated With Sirolimus- or Paclitaxel-Eluting Stents J. Am. Coll. Cardiol., October 3, 2006; 48(7): 1304 - 1309. [Abstract] [Full Text] [PDF]

				A. Colombo and S. J. Corbett Drug-Eluting Stent Thrombosis: Increasingly Recognized But Too Frequently Overemphasized J. Am. Coll. Cardiol., July 4, 2006; 48(1): 203 - 205. [Full Text] [PDF]

				S. Tsimikas Drug-Eluting Stents and Late Adverse Clinical Outcomes: Lessons Learned, Lessons Awaited J. Am. Coll. Cardiol., May 16, 2006; 47(10): 2112 - 2115. [Full Text] [PDF]